Sangamo wins interim OK for cheaper $35M Chapter 11 loan
What's the deal? Biotechnology company Sangamo Therapeutics received interim approval in July 2026 for a new $35 million Chapter 11 financing package carrying a lower interest rate.
Why now? The debtor-in-possession loan lets Sangamo access cash to keep operating while it works through bankruptcy. The lower interest rate reduces the cost of that financing.
The signal: At $35 million, the package ranks in roughly the top 8% of debt rounds among United States health companies, underscoring how sizeable restructuring financing has become in the sector.
Read more: Law360
Image credit: Generated with Gemini
